Disclosed positions
| BEAM THERAPEUTICS INC | BEAM | COM | $35,119,410 | 1,266,934 | SH | None |
| LYELL IMMUNOPHARMA INC | LYEL | COM NEW | $31,029,810 | 1,008,116 | SH | None |
| PRIME MEDICINE INC | PRME | COM | $6,218,969 | 1,792,210 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.